BRIEF: Mengniu’s profit evaporates on flood of charges

2319.HK

Dairy producer China Mengniu Dairy Com. Ltd. (2319.HK) said on Tuesday it expects to report its 2024 net profit tumbled to between 50 million yuan ($6.9 million) and 250 million yuan from 4.81 billion yuan the previous year.

It blamed the decline on several factors, including falling raw milk prices and weak consumer demand. The company also said impairment charges related to its Bellamy’s Australian subsidiary will have an expected impact of 3.8 billion to 4 billion yuan. Fair value changes for dairy cows belonging to its China Modern Dairy (1117.HK) associate added an additional 790 million yuan to 900 million yuan in losses.

The company stressed that the charges are non-cash in nature, and thus won’t have any material adverse effect on its current and future operations or cash flow. Shares of Mengniu opened up 2 % on Wednesday and continued to rise through the session. They were up about 10% in afternoon trading.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click  here

,
, , , ,

Related Articles

RELATED ARTICLES

No related posts.

Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
SY.US
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…
1093.HK